



FORM PTO-1449
(REV. 7-80)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.
390069,401

APPLICATION NO.
10/053,530

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANTS
Jeffrey A. Ledbetter et al.

FILING DATE
January 17, 2002

GROUP ART UNIT
1644 #7

Sheet 1 of 6

TECH CENTER 1600/2900

JUL 15 2002

RECEIVED

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
LM	AA	4,704,692	11/03/87	Ladner	364	496	
	AB	4,816,567	03/28/89	Cabilly et al.	530	387	
	AC	4,906,562	03/06/90	Hellstrom et al.	435	7	
	AD	4,935,495	06/19/90	Hellström et al.	530	387	
	AE	4,946,778	08/07/90	Ladner et al.	435	69.6	
	AF	5,091,177	02/25/92	Hellström et al.	424	85.8	
	AG	5,225,539	07/06/93	Winter	530	387.3	
LA	AH	5,500,362	03/19/96	Robinson et al.	455	723	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
LA	AI	WO 89/07142	08/10/89	WIPO		
	AJ					

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

LA	AK	Batra et al., "Single-Chain Immunotoxins Directed at the Human Transferrin Receptor Containing <i>Pseudomonas</i> Exotoxin A or Diphtheria Toxin: Anti-TFR(Fv)-PE40 and DT388-Anti-TFR(Fv)," <i>Molecular and Cellular Biology</i> 11(4):2200-2205, April 1991.
	AL	Beiske et al., "Triggering of Neoplastic B Cells Via Surface IgM and the Cell Surface Antigens CD20 and CDw40. Responses Differ from Normal Blood B Cells and are Restricted to Certain Morphologic Subsets," <i>Int. J. Cancer</i> 42:521-528, 1988.
	AM	Brown et al., "Treatment of B-Cell Lymphomas With Anti-idiotypic Antibodies Alone and in Combination With Alpha Interferon," <i>Blood</i> 73(3):651-661, February 15, 1989.
	AN	Chaudhary et al., "A recombinant immunotoxin consisting of two antibody variable domains fused to <i>Pseudomonas</i> exotoxin," <i>Nature</i> 339:394-397, June 1, 1989.
LA	AO	Clark et al., "Activation of human B cells mediated through two distinct cell surface differentiation antigens, Bp35 and Bp50," <i>Proc. Natl. Acad. Sci. USA</i> 83:4494-4498, June 1986.

EXAMINER

DATE CONSIDERED 3/26/03

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

Handwritten signature: David Bluh

Handwritten date: 1/6/06

FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
390069.401APPLICATION NO.
10/053,530

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANTS

Jeffrey A. Ledbetter et al.

FILING DATE

January 17, 2002

GROUP ART UNIT

1644

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
DB	LN	BA 5,530,101	06/25/96	Queen et al.	530	387.3	
		BB 5,585,089	12/17/96	Queen et al.	424	133.1	
		BC 5,597,707	01/28/97	Marken et al.	435	69.3	
		BD 5,645,835	07/08/97	Fell, Jr. et al.	424	134.1	
		BE 5,693,762	12/02/97	Queen et al.	530	387.3	
		BF 5,795,572	08/18/98	Diegel et al.	424	135.1	
		BG 5,807,734	09/15/98	Diegel et al.	435	252.33	
DB	LN	BH 5,869,620	02/09/99	Whitlow et al.	530	387.3	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION
					YES NO

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

DB	LN	BI	Davis et al., "High Level Expression in Chinese Hamster Ovary Cells of Soluble Forms of CD4 T Lymphocyte Glycoprotein Including Glycosylation Variants," <i>The Journal of Biological Chemistry</i> 265(18):10410-10418, June 25, 1990.
		BJ	Dillman et al., "Continuous Infusion of T101 Monoclonal Antibody in Chronic Lymphocytic Leukemia and Cutaneous T-Cell Lymphoma," <i>Journal of Biological Response Modifiers</i> 5(5):394-410, 1986.
		BK	Einfeld et al., "Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains," <i>EMBO Journal</i> 7:711-717, 1988.
		BL	Funakoshi et al., "Differential In Vitro and In Vivo Antitumor Effects Mediated by Anti-CD40 and Anti-CD20 Monoclonal Antibodies Against Human B-Cell Lymphomas," <i>Journal of Immunotherapy</i> 19(2):93-101, 1996.
		BM	Funakoshi et al., "Inhibition of Human B-Cell Lymphoma Growth by CD40 Stimulation," <i>Blood</i> 83(10):2787-2794, May 15, 1994.
DB	LN	BN	Hekman et al., "Initial experience with treatment of human B cell lymphoma with anti-CD19 monoclonal antibody," <i>Cancer Immunol. Immunother.</i> 32:364-372, 1991.

EXAMINER

DATE CONSIDERED

3/26/03


* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

1/6/06

RECEIVED

JUL 15 2002

TECH CENTER 1600/2910

FORM PTO-449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
390069.401APPLICATION NO.
10/053,530

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANTS

Jeffrey A. Ledbetter et al.

FILING DATE

January 17, 2002

GROUP ART UNIT

1644

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
DB LN	CA	5,876,950	03/02/99	Siadak et al.	435	7.23	
DB LN	CB	5,888,773	03/30/99	Jost et al.	435	6.26	
DB LN	CC	5,892,019	04/06/99	Schlom et al.	536	22.53	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES NO
--	--	-----------------	------	---------	-----------------------

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

DB LN	CD	Hollenbaugh et al., "The Human T cell antigen gp39, a member of the TNF gene family, is a ligand for the CD40 receptor: expression of a soluble form of gp39 with B cell co-stimulatory activity," <i>EMBO Journal</i> 11:4313-4321, 1992.
	CE	Huston et al., "Protein engineering of antibody binding sites: Recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in <i>Escherichia coli</i> ," <i>Proc. Natl. Acad. Sci. USA</i> 85:5879-5883, August 1988.
	CF	Jost et al., "Mammalian Expression and Secretion of Functional Single-chain Fv Molecules," <i>The Journal of Biological Chemistry</i> 269(42):26267-26273, October 21, 1994.
	CG	Kaminski et al., "Radioimmunotherapy of B-Cell Lymphoma with [¹³¹ I] Anti-B1 (Anti-CD20) Antibody," <i>The New England Journal of Medicine</i> 329(7):459-465, August 12, 1993.
	CH	Kato et al., "A conformational change in the Fc precludes the binding of two Fcγ receptor molecules to one IgG," <i>Immunology Today</i> 21(7):310-312, July 2000.
	CI	Koolwijk et al., "Interaction Between Hybrid Mouse Monoclonal Antibodies and the Human High-Affinity IgG FcR, huFcγRI, on U937," <i>The Journal of Immunology</i> 143(5):1656-1662, September 1, 1989.
	CJ	Ledbetter et al., "Augmentation of Normal and Malignant B Cell Proliferation by Monoclonal Antibody to the B Cell-Specific Antigen BP50 (CDW40)," <i>The Journal of Immunology</i> 138(3):788-794, February 1, 1987.
	CK	Liu et al., "Production of a Mouse-Human Chimeric Monoclonal Antibody to CD20 with Potent Fc-Dependent Biologic Activity," <i>The Journal of Immunology</i> 139(10):3521-3526, November 15, 1987.

EXAMINER

DATE CONSIDERED

3/26/03

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

1/6/06

RECEIVED
JUL 15 2002
TECH CENTER 1600/2900



Sheet 4 of 6
RECEIVED
JUL 15 2002
TECH CENTER 1600/2900

FORM PTO-1449
(REV. 7-80)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.
390069.401

APPLICATION NO.
10/053,530

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANTS

Jeffrey A. Ledbetter et al.

FILING DATE

January 17, 2002

GROUP ART UNIT

1644

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
----------------------	-----------------	------	------	-------	----------	-------------------------------

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES NO
-----------------	------	---------	-----------------------

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

DA	Maloney et al., "IDEC-C2B8: Results of a Phase I Multiple-Dose Trial in Patients With Relapsed Non-Hodgkin's Lymphoma," <i>Journal of Clinical Oncology</i> 15(10):3266-3274, October 1997.
DB	Maloney et al., "IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma," <i>Blood</i> 90(6):2188-2195, September 15, 1997.
DC	McLaughlin et al., "IDEC-C2B8 ANTI-CD20 Antibody: Final Report on a Phase III Pivotal Trial in Patients (PTS) With Relapsed Low-Grade or Follicular Lymphoma (LG/F NHL)," <i>Blood</i> 88(Abstract Suppl. 1):90a, Abstract 349, 1996.
DD	Pawson et al., "Treatment of T-Cell Prolymphocytic Leukemia With Human CD52 Antibody," <i>Journal of Clinical Oncology</i> 15(7):2667-2672, July 1997.
DE	Press et al., "Monoclonal Antibody 1F5 (Anti-CD20) Serotherapy of Human B Cell Lymphomas," <i>Blood</i> 69(2):584-591, February 1987.
DF	Press et al., "Radiolabeled-Antibody Therapy of B-Cell Lymphoma With Autologous Bone Marrow Support," <i>The New England Journal of Medicine</i> 329(17):1219-1224, October 21, 1993.
DG	Radaev et al., "The Structure of a Human Type III Fcγ Receptor in Complex with Fc," <i>The Journal of Biological Chemistry</i> 276(19):16469-16477, May 11, 2001.
DH	Radaev and Sun, "Recognition of IgG by Fcγ Receptor," <i>The Journal of Biological Chemistry</i> 276(19):16478-16483, May 11, 2001.
DI	Scheinberg et al., "A Phase I Toxicity, Pharmacology, and Dosimetry Trial of Monoclonal Antibody OKB7 in Patients With Non-Hodgkin's Lymphoma: Effects of Tumor Burden and Antigen Expression," <i>Journal of Clinical Oncology</i> 8(5):792-803, May 1990.
DJ	Sensel et al., "Engineering Novel Antibody Molecules," <i>Chemical Immunology</i> 65: 129-158, 1997.
DK	Shan et al., "Apoptosis of Malignant Human B Cells by Ligation of CD20 With Monoclonal Antibodies," <i>Blood</i> 91(5):1644-1652, March 1, 1998.

EXAMINER

DATE CONSIDERED 3/26/07

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

David B. Burt

1/6/06

FORM PTO-1449
(REV. 7-80)



U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.
390069.401

APPLICATION NO.
10/053,530

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANTS

Jeffrey A. Ledbetter et al.

FILING DATE

January 17, 2002

GROUP ART UNIT

1644

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
----------------------	-----------------	------	------	-------	----------	-------------------------------

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES NO
-----------------	------	---------	-----------------------

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

EA	Shan et al., "Characterization of scFv-Ig Constructs Generated from the Anti-CD20 mAb 1F5 Using Linker Peptides of Varying Lengths," <i>The Journal of Immunology</i> 162(11):6589-6595, June 1, 1999.
EB	Shin et al., "Hybrid Antibodies," <i>Intern. Rev. Immunol.</i> 10:177-186, 1993.
EC	Shin et al., "Genetically-Engineered Antibodies: Tools for the Study of Diverse Properties of the Antibody Molecule," <i>Immunological Reviews</i> 130:87-107, 1992.
ED	Sondermann et al., "The 3.2-Å crystal structure of the human IgG1 fragment-FcγRIII complex," <i>Nature</i> 406:267-273, July 20, 2000.
EE	Traunecker et al., "Bispecific single chain molecules (Janusins) target cytotoxic lymphocytes on HIV infected cells," <i>EMBO Journal</i> 10:3655-3659, 1991.
EF	Vlasveld et al., "Treatment of low-grade non-Hodgkin's lymphoma with continuous infusion of low-dose recombinant interleukin-2 in combination with the B-cell-specific monoclonal antibody CLB-CD19," <i>Cancer Immunol. Immunother.</i> 40:37-47, 1995.
EG	White et al., "Activation of Dense Human Tonsillar B Cells. Induction of <i>c-myc</i> Gene Expression via Two Distinct Signal Transduction Pathways," <i>The Journal of Immunology</i> 146(3):846-859, February 1, 1993.
EH	Yokota et al., "Rapid Tumor Penetration of a Single-Chain Fv and Comparison with Other Immunoglobulin Forms," <i>Cancer Research</i> 52:3402-3408, June 15, 1992.
EI	Genbank Accession No. L07414, April 27, 1993.
EJ	Genbank Accession No. M62541, July 26, 1993.
EK	Genbank Accession No. M62542, April 27, 1993.
EL	Genbank Accession No. M83312, September 23, 1996.
EM	Genbank Accession No. M84371, July 17, 1995.
EN	Genbank Accession No. U15637, March 8, 2002.

EXAMINER

DATE CONSIDERED 3/26/03

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

RECEIVED
TECHNICAL
JUL 15 2002
Sheet 5 of 6

Handwritten signature

1/6/06



Sheet 6 of 6

FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
390069.401APPLICATION NO.
10/053,530

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANTS

Jeffrey A. Ledbetter et al.

FILING DATE

January 17, 2002

GROUP ART UNIT

1644

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
FA						
FB						
FC						
FD						
FE						
FF						
FG						
FH						

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
				YES	NO
FI					
FJ					
FK					
FL					
FM					

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

FN	Genbank Accession No. X14046, September 12, 1993.
FO	Genbank Accession No. X53517, February 17, 1992.
FP	Genbank Accession No. X65453, April 26, 2001.
FQ	Genbank Accession No. X67878, June 6, 1997.
FR	Genbank Accession No. X96710, February 13, 1997.
FS	Genbank Accession No. Y10507, September 4, 1997.
FT	

EXAMINER

DATE CONSIDERED

3/24/03

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).



PTO/SB/08B (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Applicant Number	10/053,530
Filing Date	1/17/03
First Named Inventor	Ledbetter
Art Unit	1642
Examiner Name	Helms, Larry Ronald
Attorney Docket Number	49076.000004.UTL2

Sheet 1 of 2

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-Issue number(s), publisher, city and/or country where published.	T ²
DB		BREKKE et al., "The Structural Requirements for Complement Activation by IgG: Does It Hinge on the Hinge?", Immunol. Today 16:85-90 (1995)	
		BURKE et al., "Radioimmunotherapy for Acute Leukemia", Cancer Control, 9:106-113 (2002)	
		COLOMA, et al., "The Hinge as a Spacer Contributes to Covalent Assembly and Is Required for Function of IgG", J. Immunol. 158(2):733-40	
		DORAI, et al., "Role of Inter-Heavy and Light Chain Disulfide Bonds in the Effector Functions of Human Immunoglobulin IgG1", Mol. Immunology 29:1487-1491 (1992).	
		DUNCAN, et al., "The Binding Site for Clq on IgG", Nature, 322:738-740 (1988)	
		GILLIES, et al., "Antigen Binding and Biological Activities of Engineered Mutant Chimeric Antibodies with Human Tumor Specificities", Hum. Antibodies Hybridomas 1:47-54 (1990)	
		ISENMAN, et al., "Correlation between the Exposure of Aromatic Chromophores ...", Biochemistry 16:233-240 (1977)	
		KLEIN, et al., "Expression of Biological Effector Functions by Immunoglobulin G Molecules Lacking the Hinge Region", Proc. Natl. Acad. Sci. USA 78:524-528 (1981)	
		MICHAELSEN, et al., "Antibody Dependent Cell-Mediated Cytotoxicity Induced by Chimeric Mouse-Human IgG Subclasses ...", Mol. Immunol. 29:319-326 (1992)	
DB		MICHAELSEN, et al., "Enhancement of Complement Activation and Cytolysis of Human IgG3 by Deletion of Hinge Exons", Scand. J. Immunol. 32:517-528 (1990)	

Examiner Signature	<i>Paul B. Helms</i>	Date Considered	1/6/06
--------------------	----------------------	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/088 (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/053,530
Filing Date	January 17, 2002
First Named Inventor	Ledbetter
Art Unit	1642
Examiner Name	Helms
Attorney Docket Number	49076.000004.UTL2

Sheet 2 of 2

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
DB		MICHAELSEN, et al., "One Disulfide Bond in Front of the Second Heavy Chain Constant Region...", Proc. Natl. Acad. Sci. USA 91:9243-9247 (1994).	
		NIKULA, et al., "Impact of the High Tyrosine Fraction in Complementarity Determining Regions: ...", Mol. Immunol. 32:865-872 (1995)	
		REDPATH, et al., "The Influence of the Hinge Region Length in Binding of Human IgG to Human Fcγ Receptors", Hum. Immunol. 59:720-727 (1998)	
		SPELLIE, et al., "Radioimmunotherapy of Breast Cancer Xenografts with Monoclonal Antibody ICR12 ...", Cancer Res. 55:5842s-5846s (1995)	
		TAN, et al., "Influence of the Hinge Region on Complement Activation, C1q Binding, and Segmental Flexibility in Chimeric Human Immunoglobulins", PNAS, USA, 87(1):162-6	
		TAO, et al., "Role of Carbohydrate in the Structure and Effector Functions Mediated by the Human IgG Constant Region", 1989, J. Immunol. 143(8):2595-601	
		THOMMESEN, et al., "Lysine 322 in the Human IgG3 CH2 Domain Is Crucial for Antibody Dependent Complement Activation", Mol. Immunol., 37:995-1004 (2000)	
		VAN DEN ABEELE, et al., "Antigen-Binding Site Protection During Radiolabeling Leads to a Higher Immunoreactive Fraction", J. Nucl. Med. 32:116-122 (1991)	
		WALKER, et al., "Aglycosylation of Human IgG1 and IgG3 Monoclonal Antibodies Can Eliminate Recognition by Human Cells ...", 1989, Biochem. J. 259(2):347-53)	
DB		ZHOROV, et al., "Oxidative Iodination of Rabbit IgG: Localization of the Label in the Fc Fragment and Modification Effects", Biokhimiia 56:828-838 (1991)	

Examiner Signature	<i>Samuel B. Helms</i>	Date Considered	1/6/06
--------------------	------------------------	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Please type a plus sign (+) inside this box ☐ ☐

PTO/SB/08A (10-

0651-0031

Approved for use through 10/31/99. OMB

Patent and Trademark Office: U.S. DEPARTMENT OF

COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	10/053,530		
		Filing Date	1/17/02		
		First Named Inventor	Ledbetter		
		Group Art Unit	1642		
		Examiner Name	Helms		
Sheet	1	of	5	Attorney Docket Number	49076.000004.UTL2


U. S. PATENT DOCUMENTS						
Examine Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
DB	A.	5,098,833		LASKY et al.	03/24/92	
	B.	5,260,203		LADNER et al.	11/09/93	
	C.	5,434,131		LINSLEY et al.	07/18/95	
	D.	5,455,030		LADNER et al.	10/03/95	
	E.	5,521,288		LINSLEY et al.	05/28/96	
	F.	5,580,756		LINSLEY et al.	12/03/96	
	G.	5,605,690		JACOBS et al.	02/25/97	
	H.	5,637,481		LEDBETTER et al.	06/10/97	
	I.	5,709,859		ARUFFO et al.	01/20/98	
	J.	5,714,147		CAPON et al.	02/03/98	
	K.	5,770,197		LINSLEY et al.	06/23/98	
	L.	5,773,253		LINSLEY et al.	06/30/98	
	M.	5,844,095		LINSLEY et al.	12/01/98	
	N.	5,869,049		NOELLE et al.	02/9/99	
	O.	5,876,718		NOELLE et al.	03/02/99	
	P.	5,916,560		LARSEN et al.	06/29/99	
	Q.	6,087,329		ARMITAGE et al.	07/11/00	
	R.	6,090,914		LINSLEY et al.	07/18/00	
DB	S.	6,194,551 B1		IDUSOGIE et al.	02/27/01	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document by the two-letter code (WPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Examiner Signature	<i>Samuel B. Helms</i>	Date Considered	1/6/06
--------------------	------------------------	-----------------	--------




Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	10/053,530
		Filing Date	1/17/02
		First Named Inventor	Ledbetter
		Group Art Unit	1642
Examiner Name	Helms		
Sheet 2	of 5	Attorney Docket No. 49076.000004.UTL2	

U. S. PATENT DOCUMENTS					
Examine Initials*	Cite No. ¹	U.S. Patent Document	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

DB	T.	6,264,951 B1	ARMITAGE et al.	07/24/01	
	U.	6,312,692 B1	NOELLE et al.	11/06/01	
	V.	6,376,459 B1	ARUFFO et al.	04/23/02	
	W.	6,384,198 B1	DIEGEL et al.	05/07/02	
	X.	6,410,319 B1	RAUBITSCHKE et al.	06/25/02	
	Y.	6,444,792 B1	GRAY et al.	09/03/02	
	Z.	6,472,510 B1	ARUFFO et al.	10/29/02	
	AA.	6,623,940 B1	LEDBETTER et al.	09/23/03	
	AB.	6,641,809 B1	LINSLEY et al.	11/04/03	
	AC.	2001/004135 A1	STAHl et al.	11/22/01	
	AD.	2002/0031510 A1	LARSEN et al.	03/14/02	
	AE.	2002/0039557 A1	WHITE	04/04/02	
	AF.	2002/0155604 A1	LEDBETTER et al.	10/24/02	
	AG.	2003/0219436 A1	LEDBETTER et al.	11/27/03	
	AH.	2003/0219446 A1	LINSLEY et al.	11/27/03	
	AI.	2003/0219876 A1	LEDBETTER et al.	11/27/03	
DB	AJ.	2004/0058445 A1	LEDBETTER et al.	03/25/04	

FOREIGN PATENT DOCUMENTS							
Examine Initials*	Cite No. ¹	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³ known)	Kind Code ⁵ Number ⁴ (if				
DB	AK.	WO	92/00092	BRISTOL-MYERS SQUIBB COMPANY	01/09/92		
DB	AL	WO	93/00431	BRISTOL-MYERS SQUIBB COMPANY	01/07/93		
DB	AM	WO	99/42077	XCYTE THERAPIES, INC.	08/26/99		

Examiner Signature	<i>David Helms</i>	Date Considered	1/6/06
--------------------	--------------------	-----------------	--------



				Complete if Known	
				Filing Date	1/17/02
				First Named Inventor	Ledbetter
				Group Art Unit	1642
				Examiner Name	Helms
Sheet	3	of	5	Attorney Docket Number	49076.000004.UTL2

	AN	EP	0 555 880 A2		BRISTOL-MYERS SQUIBB COMPANY	08/18/93		
	AO	EP	0 757 099 A2		BRISTOL-MYERS SQUIBB COMPANY	07/21/95		
	AP	EP	0 682 039 A1		BRISTOL-MYERS SQUIBB COMPANY	11/15/95		
	AQ	EP	1 186 300 A1		BRISTOL-MYERS SQUIBB COMPANY			

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		AICHER, et al., "Characterization of Human Inducible Costimulator Ligand Expression and Function", The Journal of Immunology, 2000, 164: 4689-4696	
		CARTER, "Improving the Efficacy of Antibody-Based Cancer", Nature, November 2001, Volume 1, 118-129	
		CLARK et al., "Structure, Function, and Genetics of Human B Cell-Associated Surface Molecules", Advances in Cancer Research, Vol. 52, 81-149	
		DAMLE, et al., "Direct helper T cell-induced B cell differentiation involves interaction between T cell antigen CD28 and B cell activation antigen B7", Eur. J. Immunology 1991; 21; 1277-1282	
		DAVIES, et al., "'Camelising' Human Antibody Fragments: NMR Studies on VH Domains," FEBS Letters 339 (1994) 285-290	
		DESMYTER et al., "Crystal structure of a camel single-domain V _H antibody fragment in complex with lysozyme", Nature Structural Biology, Volume 3, Number 9, September 1996, 803-811	
		DIETSCH et al., "Coengagement of CD2 with LFA-1 or VLA-4 by bispecific ligand fusion proteins primes T cells to respond more effectively to T cell receptor-dependent signals, Journal of Leukocyte Biology, Volume 56, October 1994, 444-452	
		DIETSCH et al., "Bispecific receptor globulins, novel tools for the study of cellular interactions", Journal of Immunological Methods, 162 (1993) 123-132	
		DURIE et al., "Prevention of Collagen-Induced Arthritis with an Antibody to gp39, the Ligand for CD40", Science, Vol. 261, September 3, 1993, 1328-1330	

Examiner Signature		Date Considered	11/6/06
--------------------	--	-----------------	---------



INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if known	
		Application Number	10/053,530
		Filing Date	1/17/02
		First Named Inventor	Ledbetter
		Group Art Unit	1642
		Examiner Name	Helms
Sheet	4		5
		Attorney Docket Number	49076.000004.UTL2

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
DB		FELL et al., "Genetic Construction and Characterization of a Fusion Protein Consisting of a Chimeric F(ab') with Specificity for Carcinomas and Human IL-2", The Journal of Immunology, Vol. 146, 2446-2452, No. 7, April 1, 1991	
		FILPULA et al., "Single-chain Fv designs for protein, cell and gene therapeutics" Exp. Opin. Ther. Patents (1999) 9 (3):231-245	
		GILLILAND et al., "Rapid and Reliable Cloning of antibody Variable Regions and Generation of Recombinant Single Chain Antibody Fragments", Tissue Antigens 1996: 47: 1-20 (Denmark)	
		HAYDEN, et al., "Antibody Engineering," Curr. Opin. Immuno., 9:201-212 (1997)	
		HAYDEN, et al., "Single-chain Mono- and bispecific Antibody Derivatives With Novel Biological Properties and Antitumor Activity from a COS Cell Transient Expression System," Thera. Immuno., 1:3-15 (1994)	
		HAYDEN et al., "Costimulation by CD28 sFv expressed on the tumor cell surface or as a soluble bispecific molecule targeted to the L6 carcinoma antigen", Tissue Antigens 1996: 48; 242-254	
		HU, et al., "Minibody: A Novel Engineered Anti-Carcinoembryonic Antigen Antibody Fragment (Single-Chain Fv-CH3) Which Exhibits Rapid, High-Level Targeting of Xenografts," Cancer Res. 56(13):3055-3061 (1996)	
		HUDSON, "Recombinant antibodies: a novel approach to cancer diagnosis and therapy", Exp. Opin. Invest. Drugs (2000) 9(6):1231-1242	
		HUDSON, "Recombinant antibody fragments", Current Opinion in Biotechnology, 1998, 9:395-402	
		KORTT, et al., "Dimeric and Trimeric Antibodies: High Avidity scFvs for Cancer Targeting," Biomole. Eng., 18:95-108 (2001)	
		LEE et al., "Generation and characterization of a novel single-gene-encoded single-chain immunoglobulin molecule with antigen binding activity and effector functions", Molecular Immunology 36 (1999) 61-71	
DB		LI, et al., "Single-chain antibodies against human insulin-like growth factor I receptor: expression, purification and effect on tumor growth", Cancer Immunol. Immunother (2000) 49:243-252	


Examiner Signature	<i>David R. Helms</i>	Date Considered	1/6/06
--------------------	-----------------------	-----------------	--------



Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if known			
		Application Number	10/053,530		
		Filing Date	1/17/02		
		First Named Inventor	Ledbetter		
		Group Art Unit	1642		
		Examiner Name	Helms		
Sheet	5		5	Attorney Docket Number	49076.000004.UTL2

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
DB		LIU, et al., "Production of a Mouse-Human Chimeric Monoclonal Antibody to CD20 With Potent Fc-Dependent Biological Activity," <i>J. Immunol.</i> 139(10):3521-3526 (1987)	
		MULTANI et al., "Monoclonal Antibody-Based Therapies for Hematologic Malignancies", <i>Journal of Clinical Oncology</i> , Vol. 16, No 11 (November), 1998: pp 3691-3710	
		PARK et al., "Generation and Characterization of a Novel Tetravalent Bispecific antibody that binds to hepatitis B virus surface antigens", <i>Molecular Immunology</i> 37 (2000) 11-23-1130	
		SEGAL et al., "Introduction: bispecific antibodies", <i>Journal of Immunological Methods</i> , 248 (2001) 1-6	
		SHU et al., "Secretion of a single-gene-encoded immunoglobulin from myeloma cells", <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 90, 7995-7999, September 1993	
		SOURIAU et al., "Recombinant antibodies for cancer diagnosis and therapy", <i>Expert Opin. Biol. Ther.</i> (2003) 3(2):305-318	
		SPORICI et al., "ICOS Ligand Costimulation Is Required for T-Cell Encephalitogenicity", <i>Clinical Immunology</i> , Vol. 100, No. 3, September, pp. 277-288, 2001	
DB		WU, et al., "Multimerization of a Chimeric Anti-CD20 Single-chain Fv-Fc Fusion Protein is Mediated Through Variable Domain Exchange," <i>Protein Eng.</i> , 14(12):1025-1033 (2001)	

Examiner Signature	<i>Donald B. Helms</i>	Date Considered	1/6/06
--------------------	------------------------	-----------------	--------



PTO/SB/08A (08-03)

Approved for use through 07/31/2008. OMB 0851-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for Form 1449/PTO
TRADEMARK OFFICE**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/207,635 10/053530
Filing Date	July 25, 2002
First Named Inventor	LEDBETTER
Art Unit	1642
Examiner Name	HELMS, LARRY R.
Attorney Docket Number	49076-000004.uit2

Sheet 1 of 2

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² of Inventor			
DB		US- 5844093	12-01-1998	MERCK PATENT GMBH (D	
		US- 5736137	04-07-1998	RASTETTER W. et al	
		US- 5776456	07-07-1998	RASTETTER W. et al	
		US- 20030133930	07-17-2003	Goldenberg et al.	
		US- 2003-0219433	02-14-2003	Hansen H.	
		US- USCN 09/596,284	08-09-2000	Goldenberg et al.	
		US- 6147203	11-14-2000	Pastan et al.	
		US- 6074644	06-13-2000	Pastan et al.	
		US- 5677425	10-14-1977	Bodmer et al.	
		US- 6482919	11-19-2002	Ledbetter et al.	
DB		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS


Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	† ³
		Country Code ² Number ⁴ Kind Code ⁵ (if known)				
DB		WO0044777	08-03-2000	IMCLONE SYSTEMS		
		WO9221755	12-10-1992	GENENTECH INC		
		EP0586002	03-09-1994	Macineira et al		
		WO9509917	04-01-1995	COLOMA et al.		
		WO9405690	03-17-1994	Gross et al.		

Examiner Signature		Date Considered	2/4/05 1/6/06
-----------------------	--	--------------------	---------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/088 (08-03)

Approved for use through 07/31/2008. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/053,530
Filing Date	January 17, 2002
First Named Inventor	LEDBETTER
Art Unit	1642
Examiner Name	HELMS, LARRY R
Attorney Docket Number	49076-000004.utl2

Sheet 2 of 2

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
DB	2A	Munoz E. et The C(H)1 domain of IgG is not essential for C3 covalent binding: importance of the other constant domains as targets for C3. Int Immunol. 1998 Feb;10(2):97-106.	
	2B	Martin S. et al., Efficient neutralization and disruption of rhinovirus by chimeric ICAM- 1/immunoglobulin molecules , J. Virol. 1993;67:3561-3568	
	2C	Stevenson G.T. et al., Mechanisms in removal of tumor by antibody. Cell Biophys. 1994;24-25:45-50.	
	2D	Anderson et al., Targeted anti-cancer therapy using rituximab, a chimeric anti-CD-20 antibody (IDEC-c2B8) in the treatment of non-hodgkin's B-cell lymphoma; Biochemical Society Transactions Colcester, Essex, GB, pg 705-708; 1997	

Examiner Signature		Date Considered	2/4/05 1/6/06
--------------------	--	-----------------	---------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.